Instrument Inactif

Communiqués Vifor Pharma Deutsche Boerse AG

Actions

G2AA

CH0364749348

Produits pharmaceutiques

Communiqués

14/12/22	Cancellation of remaining publicly held registered shares of Vifor Pharma AG	BU
28/11/22	Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	BU
25/11/22	Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	BU
20/10/22	Approval of extension of exemptions from SIX disclosure and publicity obligations	BU
12/10/22	Approval of delisting of Vifor Pharma AG's registered shares	BU
22/08/22	CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy	BU
22/08/22	VFMCRP announces U.S. Court upholds validity of Velphoro® patent	BU
19/08/22	Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022	BU
18/08/22	Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)	BU
02/08/22	Finalization of Vifor Pharma acquisition	BU
13/07/22	Extension of the postponement of the settlement of Vifor Pharma tender offer	BU
22/06/22	THE EU COMMISSION OPENS ANTITRUST INVESTIGATION INTO COMPETITORS SUSPECTED ILLEGAL DISPARAGEMENT OF PHARMACOSMOS' MAIN INTRAVENOUS IRON PRODUCT	AQ
12/05/22	Update on the timeline for Vifor Pharma tender offer	BU
26/04/22	94th Vifor Pharma Group Annual General Meeting	BU
04/04/22	DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy	BU
28/03/22	Publication of definitive end result for Vifor Pharma tender offer	BU
23/03/22	Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent	BU
03/03/22	Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent	BU
02/03/22	CORDENPHARMA COMPLETES ACQUISITION OF 3 FACILITIES FROM VIFOR PHARMA	AQ
28/02/22	Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients	BU
17/02/22	Vifor Pharma : INVESTOR FACTSHEET	PU
17/02/22	Vifor Pharma : Annual Report 2021 – Full Version	PU
17/02/22	Vifor Pharma reports sustained growth in 2021	BU
02/02/22	Vifor Pharma appoints two new members to the Executive Committee	BU
19/01/22	VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis	BU